In vitro activity of linezolid against Staphylococcus aureus: A population study

Chemotherapy

Volumn 51, Issue 2-3, 2005, Pages 86-88

  Rodríguez, Juan C ^a   Álvarez, José M ^a   Escribano, Isabel ^a   Royo, Gloria ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Linezolid; Resistant subpopulations; Staphylococcus aureus

Indexed keywords

LINEZOLID; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL PRACTICE; MICROORGANISM; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TIME SERIES ANALYSIS;

ACETAMIDES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS;

EID: 22144451511     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085615     Document Type: Article

References (24)

1. Fluckiger U, Widmer AF: Epidemiology of methicillin-resistant Staphylococcus aureus. Chemotherapy 1999;45:121-134.
2. Lutfor AB, Kikuchi T, Tokue Y, Takahashi H, Shoji S, Fujimura S, Nukiwa T, Watanabe A: Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant Staphylococcus aureus and Enterococcus faecium in the Tohoku district of Japan. Chemotherapy 1998;44:318-323.
3. Qadri SM, Halim M, Ueno Y, Saldin H: Susceptibility of methicillin-resistant Staphylococcus aureus to minocycline and other antimicrobials. Chemotherapy 1994;40:26-29.
4. Peterson LR, Cooper I, Willard KE, Fasching CE, Sinn LM, Shanholtzer CJ, Gerding DN: Activity of twenty-one antimicrobial agents including 1-ofloxacin against quinolone-sensitive and -resistant, and methicillin-sensitive and-resistant Staphylococcus aureus. Chemotherapy 1994;40:21-25.
5. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML: Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-451.
6. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, Taylor L, Hayman S, Shaw S, Kibbler C, Shulman R, Singer M, Wilson AP: Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: A randomized, double-blind, multicentre study. J Antimicrob Chemother 2004;53:345-355.
7. Shorr AF, Susla GM, Kollef MH: Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin. Crit Care Med 2004;32:137-143.
8. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH: Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-1797.
9. Jones ME, Visser MR, Klootwijk M, Heisig P, Verhoef J, Schmitz FJ: Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphyloco ccus aureus strains. Antimicrob Agents Chemother 1999;43:421-423.
10. Patel R, Piper KE, Rouse MS, Steckelberg JM: Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother 2000;44:3438-3440.
11. Dailey CF, Dileto Fang CL, Buchanan LV, Oramas-Shirey MP, Batts DH, Ford CW, Gibson JK: Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:2304-2308.
12. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hatkin B: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-1490.
13. Bert F, Clarissou J, Durand F, Delefosse D, Chauvet C, Lefebvre P, Lambert N, Branger C: Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol 2003;41:5147-5152.
14. Moore MR, Perdreau-Remington F, Chambers HF: Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003;47:1262-1266.
15. Tenover FC, Biddle JW, Lancaster MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327-332.
16. Sugino Y, Iinumab Y, Ichiyama S, Ito Y, Ohkawa S, Nakashima N, Shimokata K, Hasegawa Y: In vivo development of decreased susceptibility to vancomycin in clinical isolates of methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2000;38:159-167.
17. Andrade Baiocchi S, Tognim MC, Baiocchi OC, Sader HS: Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: Case report and strain characterization. Diagn Microbiol Infect Dis 2003;45:149-152.
18. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D: Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001;39:2439-2444.
19. Boyle Vavra S, Berke SK, Lee JC, Daum RS: Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2000;44:272-277.
20. Stockdale MW, Tysall L, Johnson AP, Livermore DM, Woodford N: Low in vitro selection frequencies of enterococcal and staphylococcal mutants resistant to the oxazolidinone AZD2563. Int J Antimicrob Agents 2004;23:88-91.
21. Bernardo K, Pakulat N, Fleer S, Schnaith A, Utermohlen O, Krut O, Muller S, Kronke M: Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004;48:544-546.
22. Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ, Robbins M: Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003;51:186-188.
23. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-208.
24. Meka VG, Gold HS, Cooke A, Venkataraman L, Eliopoulos GM, Moellering RC Jr, Jenkins SG: Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemother 2004;54:818-820.